Shionogi & Co logo

4507 - Shionogi & Co News Story

¥6234 32.0  0.5%

Last Trade - 14/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £13.56bn
Enterprise Value £11.07bn
Revenue £2.23bn
Position in Universe 68th / 3863

BRIEF-GSK Says Long-Acting Injectable Cabotegravir 66% More Effective Than Truvada

Tue 7th July, 2020 4:40pm
July 7 (Reuters) - ViiV Healthcare:
    * GSK'S VIIV - DATA SHOWS LONG-ACTING INJECTABLE
CABOTEGRAVIR
GIVEN EVERY TWO MONTHS 66% MORE EFFECTIVE VERSUS DAILY PILLS IN
STOPPING HIV ACQUISITION
    * VIIV HEALTHCARE - EFFICACY OF CABOTEGRAVIR COMPARED TO
DAILY
ORAL EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 200 MG AND 300
MG (FTC/TDF) TABLETS
    * VIIV HEALTHCARE - LONG-ACTING CABOTEGRAVIR, FTC/TDF
TABLETS BOTH
WELL TOLERATED THROUGHOUT STUDY
    * VIIV - MOST PARTICIPANTS IN CABOTEGRAVIR GROUP (80%)
REPORTED
PAIN OR TENDERNESS AT INJECTION SITE VERSUS 31% OF THOSE IN
FTC/TDF ARM, WHO GOT PLACEBO
    * VIIV HEALTHCARE - PLANS TO USE DATA FROM HPTN 083 FOR
FUTURE
REGULATORY SUBMISSIONS
    * VIIV HEALTHCARE - MOST ADVERSE EVENTS OF STUDY MILD OR
MODERATE
IN NATURE AND BALANCED BETWEEN BOTH TREATMENT ARMS
    * VIIV - STUDY CONDUCTED IN MEN WHO HAVE SEX WITH MEN,
TRANSGENDER
WOMEN WHO HAVE SEX WITH MEN; FURTHER STUDY BEING CONDUCTED IN
SEXUALLY ACTIVE WOMEN

Further company coverage:  GSK.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.